Cargando…
High response rate to PD-1 blockade in desmoplastic melanomas
Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, but is highly associated with ultraviolet light DNA damage.(1) We analysed 60 patients with advanced DM treated with programmed cell d...
Autores principales: | Eroglu, Zeynep, Zaretsky, Jesse M., Hu-Lieskovan, Siwen, Kim, Dae Won, Algazi, Alain, Johnson, Douglas B., Liniker, Elizabeth, Kong, Ben, Munhoz, Rodrigo, Rapisuwon, Suthee, Gherardini, Pier Federico, Chmielowski, Bartosz, Wang, Xiaoyan, Shintaku, I. Peter, Wei, Cody, Sosman, Jeffrey A., Joseph, Richard, Postow, Michael A., Carlino, Matteo S, Hwu, Wen-Jen, Scolyer, Richard A., Messina, Jane, Cochran, Alistair J., Long, Georgina V., Ribas, Antoni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773412/ https://www.ncbi.nlm.nih.gov/pubmed/29320474 http://dx.doi.org/10.1038/nature25187 |
Ejemplares similares
-
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
por: Kanz, Bridgette A., et al.
Publicado: (2016) -
What does PD-L1 positive or negative mean?
por: Ribas, Antoni, et al.
Publicado: (2016) -
Exosomes as a predictor tool of acquired resistance to melanoma treatment
por: Goedert, Lucas, et al.
Publicado: (2014) -
Circulating biomarkers to monitor cancer progression and treatment
por: Rapisuwon, Suthee, et al.
Publicado: (2016) -
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)